DePuy Orthopaedics News

The firm is actively filing DePuy Pinnacle lawsuits on behalf of individuals who allegedly suffered metallosis, premature device failure and other serious complications related to the metal-on-metal hip implant.

Johnson & Johnson expects to file for Food and Drug Administration approval of more than 10 new drugs over the next four years, the drug maker said Thursday.

Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during a review of the health care giant's medicine business.

Health-care giant Johnson & Johnson plans to seek approval for 10 new treatments to combat cancer, Hepatitis C, schizophrenia and influenza over the next four years, the company said Thursday.

The firm set an "underperform" rating on the stock. A number of other firms have also recently commented on JNJ.

Johnson & Johnson says it plans to submit more than 10 new treatments to regulators for approval and 25 applications for additional uses of approved drugs by 2017.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! In the wake of scandals and investigations over manufacturing gaffes, countless product recalls and questionable marketing practices, Johnson & Johnson is embarking on a round of corporate soul searching.

The firm is actively filing DePuy ASR lawsuits on behalf of those who allegedly suffered metallosis, premature device failure, or other serious complications related to the 2010 DePuy ASR recall.

The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Johnson and Johnson could be sourcing commercial quantities of poppies outside Tasmania in 2015.

Johnson & Johnson, the world's biggest maker of health-care products, said it will stop selling metal-on-metal and ceramic-on-metal hip replacements as demand wanes for the devices and U.S. regulators seek new rules.

Assessing whether a stock is a "value play" or a "value trap" has become a popular hobby for financial writers.

In this article, I'm going to show how much Johnson & Johnson stock is worth according to a Warren Buffett "owner earnings" style analysis.

Nanex LLC founder Eric Hunsader presented on High Frequency trading at Wired's Business Conference , and he showed this powerful video of half a second of trading in Johnson & Johnson .

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! A much-anticipated settlement of various federal government probes into Johnson & Johnson marketing of the Risperdal antipsychotic, as well as other medications, is being delayed over language the health care giant fears may cause difficulties for a raft of ... (more)

Medical Device Companies Eke Out Growth In Tough Market, Finds Latest Kalorama Report In the U.S. Medicare, Medicaid, as well as state governments implemented anemic spending increases to hospitals, the key buyer of medical device products.The beginning of 2013 saw the medical device industry make the first payments to the IRS for a new 2.3% ... (more)

The pharmaceutical industry has been subject to a major patent cliff as some of the strongest products lost patent protection.

In a new global study carried out among 412 patient groups from 39 different countries Coloplast is ranked at the very top in front of large international competitors such as Johnson & Johnson and Smith & Nephew.

With the S&P 500 having hit new all-time record highs on Friday, it's a good time to take a look back and see where the index's most recent gains have come from.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Johnson & Johnson may have a new image campaign to help consumers, investors and physicians overlook the cascade of recalls and scandals , but such promotional efforts are no substitute for improved manufacturing procedures.